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Twin studies consistently indicate important genetic influences on multiple aspects ofsmoking
behavior, including both initiation and cessation; however, knowledge rgading the role ofspe-
cific genes isextremelylimited Habit-forming actions ofnicotine appearto betriggeredprimari-
lyat nicotinic receptors on the cell bodies ofdopamine neurons in the mesolimbic"reward"
system ofthe brain, a regon implicate in addiction to other substances including cocaine, opi-
ates, and alcohol. Importantaspect ofthe dopaminergic pathwayinclude synthesis ofdopamine
in dopaminergic neurons, release ofdopamine by presynaptic neurons, receptor activation of
postsynaptic neurons, dopamine re-uptake by presyaptic neurons, and metabolism ofreleased
dopamine. Re ch e nig the role ofalielicvariation in genes involved in these functions is
being activelypursuedwith respect to addictive behavior aswel aspernlt traits and psycho-
and neuropathologic conditions and has implications for smoking research. In addition, genetic
differences in nicotinic receptors or nicotine metabolism might reaonably be hypothesized to
playarolein smokingaddiction.Aroleofdopaminergic orothergenes i smokingcessation isof
particular potential importnce, as research in this area may lead to the identification ofsub-
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The reduction of adult use of tobacco has
slowed considerably in recent years (1),
highlighting the need for new insights into
determinants of smoking behavior. It has
been hypothesized that, as overall rates of
smoking decline in response to social pres-
sures, genetic influences may be particularly
strong within the remaining population of
smokers (2). Twin studies consistently indi-
cate important genetic influences on multi-
ple aspects of smoking behavior, including
initiation, persistence, and cessation (3-7);
however, knowedge regarding specific genes
involved is extremelylimited.
Recent evidence suggests that the addic-
tive effects of tobacco constituents such as
nicotine operate primarily through dopamine
neurotransmission in the mesolimbic
"reward" system of the brain, in a manner
similar to that of other addictive substances
such as cocaine, opiates, and alcohol (8-11).
In May 1997, the U.S. Food and Drug
Administration approved Zyban (bupropion)
as the first non-nicotine-based smoking ces-
sation aid; the mechanisms of action of this
agent, while incompletely understood,
involve dopaminergic stimulation (12-14). A
role ofdopaminergic genes in smoking cessa-
tion is thus of particular importance, as
research in this area may eventually lead to
the identification of genetic subgroups of
individuals for whom dopaminergic cessation
aids maybeparticularly efficacious.
Some candidate genes involved in
dopaminergic function have previously been
identified (15,16) and are of interest to
researchers involved in a wide range of
addictive and other behavioral disorders.
These are genes that code for enzymes
involved in the synthesis or metabolism of
dopamine, dopamine receptors, and the
dopamine transporter. For many of the
genes ofinterest, polymorphisms have been
only recently identified, and, among identi-
fied polymorphisms, there is a range oflike-
ly functional significance. Knowledge in
this area is rapidly proliferating. Other
genes, including some of the cytochrome
P450 family as well as the nicotinic acetyl-
choline receptor, are involved in neural
activity or metabolism ofnicotine and have
known polymorphisms, such that these
genes may also be considered reasonable
candidates to influence smoking behavior.
Evidence for Genetic Influences on
Smoking Behavior: Twin Studies
Initial support for a genetic influence on
the use of tobacco came from cross-sec-
tional studies in twins and showed a mean
heritability (that is, the proportion ofphe-
notypic variation attributed to genetic vari-
ation) ofcigarette smoking of0.53 (range,
0.28-0.84) (3,4). Carmelli et al. (4) used
data from a registry ofmale twins to exam-
ine hereditary influences on specific aspects
of smoking behavior such as never smok-
ing, former smoking, and quitting. A
genetic influence on each of these aspects
oftobacco dependence was observed. In an
initial survey in 1967-1969, concordance
was higher among mono- than dizygotic
twins for both never and former smoking.
Quitting during the subsequent 16-year
interval was also more commonly observed
among mono- than among dizygotic twins.
Heath and Martin (5) examined genetic
influence on smoking persistence in a survey
ofAustralian twin pairs and reported higher
monozygotic correlations ofsmoking persis-
tence in both sexes than the corresponding
like-sex dizygotic correlations, consistent
with the presence ofagenetic influence. The
genetic effect on persistence appeared to be
unrelated to effects on smoking initiation.
In a study of 434 female twin pairs in the
Kaiser Permanente Women Twins Study,
Edwards et al. (7) reported findings consis-
tent with genetic influences on both former
and current smoking at both the initial and
10-year follow-up examinations [concor-
dance ratio in mono- versus dizygotic twins
= 1.6; 95% confidence interval (CI)
1.0-2.3, and 1.8, CI 1.3-2.4, respectively].
This increased concordance in monozygotic
twins remained apparent after adjustment
for age, education, and frequency ofcontact
between co-twins (a marker ofthe degree of
similarity ofenvironmental factors).
Shared genetic influences on psy-
chopathology and smoking behavior, or on
smoking and other addictive behaviors such
as alcoholism, have been hypothesized.
Kendler et al. (17), in a study of 1,566
female twins, reported an association
between smoking and major depression that
appeared to reflect a shared genetic predis-
position to both conditions. Swan et al.
(18), using data from the National Heart,
Lung, and Blood Institute's Twin Study,
reported a common genetic influence on
smoking, alcohol and coffee use, with 36%
ofthe heritability ofsmoking attributed to a
shared susceptibility to these substances.
Although twin studies provide supportive
evidence for the role of genes in smoking
behavior, none have provided clues as to spe-
cific genes that may be involved. Further, the
interpretation of twin studies is limited by
their assumption that environmental influ-
ences are similar for monozygotic and dizy-
gotic twins; thus, ifmonozygotic twins inter-
actwith and influence one another more than
do dizygotic twins, estimates ofheritability
may be inflated (19). Studies of specific
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candidate genes will be important to advance
knowledge ofgenetic influences onsmoking.
The Dopaminergic Reward System
andAddictive Behavior
Addictive drugs stimulate a neural "reward
pathway" in the the limbic system of the
brain, which controls basic emotions and
behaviors and provides a physiological basis
for the perception of pleasure (20).
Pathways ofthis system, which originate in
the ventral tegmental area (VTA) and trav-
el primarily to the nucleus accumbens
(NA), are composed ofdopaminergic neu-
rons. Amphetamine and cocaine increase
extracellular dopamine by displacing it
from presynaptic sites and by blocking
dopamine re-uptake, respectively. Opiates,
ethanol, and nicotine increase extracellular
dopamine by stimulating the firing of
dopaminergic neurons (21). In addition,
addiction to these substances may alter the
normal production of dopamine, so that
discontinuing use after addiction has
occurred may trigger withdrawal (9,20,22).
Appreciation of the importance of the
dopamine pathway in addictive behavior has
led to increasing interest in the design of
therapies aimed at this pathway (23,24).
Also, research examining the role of allelic
variation in genes involved in dopamine syn-
thesis, transport, receptor activity, and degra-
dation is being actively pursued with respect
to addictive behavior (16,25,26), personality
traits (27,28), and psycho- and neuropatho-
logicconditions (15,25).
Effects ofCigarette Smoking and
Nicotine on the Dopaminergic
Reward System
Nicotine is believed to be the primary com-
ponent oftobacco that motivates continued
use (29). The behavioral and neurobiological
effects ofnicotine are similar to other drugs
that are known to beaddictive (8,30). Habit-
forming actions ofnicotine appear to be trig-
gered primarily at nicotinic receptors on the
cell bodies ofdopaminergic neurons in the
VTA that project to the NA-i.e., the
"reward" pathway (9-11). In animal studies,
nicotine stimulates dopamine neurotransmis-
sion in the outershell ofthe NAin amanner
similar to that ofother addictive drugs such
as cocaine, amphetamine, and morphine (8).
Nicotine-induced dopamine release is signifi-
cantly reduced by mecamylamine, an antag-
onist ofcentral nervous system (CNS) nico-
tinic receptors, but is not influenced by
blockage ofperipheral (non-CNS) nicotinic
receptors (21). Destruction ofthe mesolim-
bic system attenuates the rewarding effects of
intravenous nicotine (31). VTA injections of
the nicotinic agonist cytisine are rewarding,
and both VTA and systemic injection of
dopamine antagonists disrupt intravenous
nicotineself-administration (9,11).
Experimental evidence in humans also
supports a role for dopaminergic processes in
nicotine addiction, although the precise
response to nicotine antagonists differs. In
both human cigarette smokers and animals
exposed to intravenous nicotine self-adminis-
tration, useofnicotinedecreases over time in
the presence of the nicotinic antagonist
mecamylamine. Unlike animals, however,
human smokers show an initial transient
increase in smoking, which has been hypoth-
esized to represent an attempt to compensate
for nicotinic receptorblockade (11).
Diverse neurologic disease processes pro-
vide further indirect evidence ofan interrela-
tionship between cigarette smoking and
dopaminergic effects. Schizophrenia is associ-
ated with alterations in dopaminergic trans-
mission, and the effect of nicotine on mid-
brain dopamine systems has been suggested
to partially explain the extremelyhigh preva-
lence (90%) of tobacco smoking in schizo-
phrenics (10,32). In contrast, anegative asso-
ciation ofsmoking with risk of Parkinson's
disease, a condition characterized by loss of
nigrostriatal dopamine neurons, has been
consistendy reported (33,34). The efficacyof
nicotine as a treatment for tremor in
Parkinson patients is currently under investi-
gation (35). It has also been suggested that
the mesolimbic dopamine system is involved
in some formsofdepression (10).
Compounds other than nicotine in
tobacco may also affect the rewarding effects
of cigarette smoking. Monoamine oxidases
A and B, which are involved in the oxida-
tion and degradation ofdopamine, are par-
tially inhibited in the brains ofsmokers due
to a tobacco constituent other than nicotine
(36,37). Increased availability ofdopamine
to chronic smokers arising from this inhibi-
tion may enhance the addictive power of
nicotine. Also, neurologic pathways other
than the mesolimbic pathwaymaybe direct-
ly or indirectly affected by tobacco con-
stituents and may contribute to other rein-
forcing effects and learned behaviors that
playarole in smokingaddiction (29).
Candidate Genes forSmoking
Behavior: Dopaminergic System
Important components ofthe dopaminergic
pathway include 1) synthesis of dopamine
in dopaminergic neurons; 2) release of
dopamine bypresynaptic neurons; 3) recep-
tor activation of postsynaptic neurons; 4)
dopamine re-uptake by the presynaptic
neuron, and 5) metabolism of released
dopamine. Many candidate genes involved
in dopaminergic neurotransmission have
been characterized and have identified poly-
morphisms, including those for tyrosine
hydroxylase (TH), the dopamine trans-
porter (DATI), dopamine receptors
(DRDJ-DRD5), dopamine 3-hydroxylase
(DBH), catechol-o-methyltransferase
(COMJ), and monoamine oxidase (MO)
Aand B (Table 1) (15).
In addition to smoking, genes involved
in dopamine function are of interest to
researchers in a variety of areas, including
other addictive behaviors (such as alcoholism
and cocaine abuse), as well as disorders that
occur more or less commonly among smok-
ers or substance abusers than in the general
population (such as schizophrenia, affective
disorders, and Parkinson's disease). I have
drawn from this broad literature, in addition
to genetic studies specific to smoking, in the
following discussion ofspecific polymor-
phisms ofdopaminergic genes that may play
arole insmokingbehavior.
Synthesis
Tyrosine, an amino acid that is abundant in
dietary proteins, is the starting point for
biosynthesis of dopamine. Tyrosine enters
dopaminergic neurons and is converted to
dihydroxyphenylalanine (L-DOPA) by TH;
this reaction is considered the rate-limiting
step in dopamine biosynthesis (38,39).
Subsequent conversion of L-DOPA to
dopamineinvolves the actionofan additional
enzyme, aromaticaminoaciddecarboxylase.
The TH gene has been evaluated in
many disorders related to dopaminergic
function, including alcoholism, bipolar
affective disorder, unipolar affective disor-
der, schizophrenia, and Parkinson's disease
(40-46). Initial studies made use ofbiallel-
ic restriction fragment length polymor-
phisms (RFLPs), including a TaqI site 1 kb
upstream ofthe THtranscription initiation
site, a BglII RFLP located at the 3' end of
the THgene, and a PstI RFLP (47).
A five-allele tetranucleotide repeat poly-
morphism in the first intron of the TH
gene has also been identified (48) and has
Table 1. Role ofidentified genes involved inthe dopaminergic reward pathway
Function Relevant genes
Dopamine synthesis Tyrosine hydroxylase (TH)
Receptor activation Dopamine receptors (DRD1, DRD2, DRD3, DRD4, DRD5)
Re-uptake Dopamine transporter(DATI)
Metabolism Catechol-o-methyltransferase (COMi)
Monoamine oxidase A and B(MAOA, MAOB)
Dopaminej-hydroxylase (DBI
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been used in a number of studies
(40,42,44,46,49,50). Five different DNA
fragments (260, 256, 252, 248, and 244
bp) were denoted as KI, K2, K3, K4, and
K5 alleles, respectively, according to
Polymeropoulos et al. (48). Using this poly-
morphism, Jonsson et al. (39) reported a
correlation of TH genotype with homova-
nillic acid (HVA) concentrations (a measure
ofbrain dopamine metabolism) in the cere-
brospinal fluid of healthy individuals.
Individuals with at least one copy ofthe KI
allele (69.7%) had significantly reduced
HVA levels relative to individuals lacking
the KI allele (30.3%; mean HVA = 165 vs.
206 nmol/l, respectively; p = 0.032). It has
been suggested that first-intron sequences
in the THgene may play a role in alterna-
tive splicing events that result in four types
ofmRNAofthis gene (40).
Most recently, a base pair mutation lead-
ing to aVal-81 to Met substitution in the sec-
ond exon ofthe gene has been reported (51)
and used in an association study ofbipolar
disorder (52). The Val-81 to Met polymor-
phism was present in heterozygous form in
57.1%, and in homozygous form in 11.5%,
ofhealthyindividuals in aGermanstudy (51).
Re-uptake
In presynaptic dopaminergic neurons,
dopamine is transported from the cytoplasm
to specialized storage vesicles. With the
arrival of an action potential, these vesicles
discharge their contents into the synapse
(38,53). Presynaptic nerve terminals possess
specialized dopamine transporters. Termi-
nation ofneurotransmission is accomplished
by rapid removal of dopamine from the
synapse by re-uptake into the nerve terminal
from which it was released via the dopamine
transporter or by being metabolized into an
inactive compound (32).
A polymorphic 40-base variable number
tandem repeat (VNTR) has been identified
in the 3' untranslated region of the DAT]
gene (54). Although it is unlikely this
VNTRhas functional relevance, it is close to
the coding region and may be in linkage dis-
equilibrium with a mutation that alters gene
expression or protein structure; to date, no
functional mutations of DAT] have been
reported (55). In white and black
Americans, DAT] VNTR copy number
varies between 3 and 11, with more than
90% ofindividuals displaying alleles with 9
or 10 copies (54,56). Associations of the
DAT] VNTR with attention-deficit disor-
der, schizophrenia, cocaine-induced para-
noia, and alcoholism accompanied by deliri-
um or withdrawal seizures have been report-
ed (55-58). Association studies examining
the role of DAT] in other disorders have
been negative (49,59). In 1997, Caporaso et
al. (60) reported a significant association
between DAT] genotype (specifically, with
presence ofthe 9-repeat allele) and smoking
in a comparison of 233 smokers and 233
race- and gender-matched controls.
Receptors
Multiple types of dopamine receptors have
been identified and characterized and can be
grouped into two classes (38,61-64). The
Dl class ofdopamine receptors contains the
Dl and D5 (sometimes referred to as D1A
and D1B, respectively) receptor subtypes; the
D2 class includes the D2, D3, and D4
receptor subtypes. 'When activated, Dl-like
subtypes stimulate adenylate cyclase activity
and increase cyclic AMP; D2-like receptor
subtypes generally inhibit adenylate cyclase
activity. Differences among receptor sub-
types in their response to various pharmaco-
logic agents is currently under investigation
in the development ofnew therapies for con-
ditions such as Parkinson's disease, schizo-
phrenia, and addictive disorders (38,61-65).
Polymorphisms of each of the dopamine
receptor genes (DRD], DRD2, DRD3,
DRD4, and DRDS) have been identified and
examined in association studies of various
conditions influenced by dopaminergic neu-
rotransmission.
DRD1. Four polymorphic sites ofDRD]
were initially identified by single-strand con-
formational analysis (SSCA) (66). These
include two sites in the 5' untranslated
region (UTR); one rare, silent polymor-
phism in codon 421; and one site in the 3'
UTR. Mutation screening of the coding
sequence of this gene in 131 schizophrenics
using dideoxy fingerprinting identified no
polymorphisms that altered the amino acid
sequence (67). The 5' flanking region of
DRD] contains a functional promoter;
screening for mutations in this region among
individuals with schizophrenia, bipolar dis-
ease, and healthy controls using SSCA
revealed six single base substitutions, none of
which was located in regions known to have
an influence on transcriptional activity (68).
Using the Bsp 1286I RFLP ofDRDI located
in the 3' UTR, no evidence was found for
an association with alcoholism (69). In a
studyofsmoking and DRD] polymorphisms
that used the DdeIpolymorphism located in
the 5' UTR, a significant increase in the fre-
quency of homozygosity for either the
DRD] 1- or 2-allele was reported in smokers
relative to nonsmoking controls (70).
Among smokers, homozygosity of DRDI
was also associated with number ofcigarettes
smoked per day. The mechanism of action
ofthis apparent heterozygous advantage/dis-
advantage (if real) is unknown. These
authors suggest that, because the DRD]
DcdeIpolymorphism is a neutral base change,
the association, if real, may reflect linkage
disequilibrium with mutations in regions at
or near the DRDJ locus that affect receptor
function ordensity.
DRD2. Following an initial report of a
positive association between alcoholism and
presence of the Al allele of a TaqI RFLP
(located 10 kb downstream of the coding
sequence of DRD2), DRD2 has been the
focus ofnumerous association studies exam-
ining alcoholism, cocaine addiction, smok-
ing, schizophrenia, and other disorders. A
search for functional variants in the coding
region (exons 2-8) of DRD2 identified
three infrequent variants that altered the
amino acid sequence of the receptor (Ser-
311 to Cys, Val-96 to Ala, and Pro-310 to
Ser) (71,72). In 1997, a search for function-
al variants in the promoter region (5' flank-
ing region and first exon) of the gene was
conducted; two polymorphisms were iden-
tified, and cell culture experiments suggest
reduced function associated with the dele-
tion allele of one of these polymorphisms
(-141C Ins/Del) (73). Association studies of
DRD2 have not yielded consistent results
and have generated considerable controver-
sy, particularly regarding the possible role of
DRD2 in alcoholism (74-78). While the
bulk ofresearch published to date has used
the Taqi allele system, other nonfunctional
RFLPs have also been examined, as has the
Ser-311 to Cys polymorphism. The recent-
ly identified -141C Ins/Del polymorphism
has been assessed in only one study to date,
in which a reduced frequency ofthe -141C
Del allele was reported among 260 schizo-
phrenic patients relative to 312 controls
[odds ratio (OR) = 0.6, CI 0.44-0.81) (73).
Recent contributions to the DRD2liter-
ature have noted the need for additional
studies of DRD2 and substance abuse and
the need for improved methodology. Two
strategies have been recommended, includ-
ing further examination of functional vari-
ants of DRD2 (79) and DRD2 haplotypes,
as a means to reduce the possible confound-
ing effects of ethnic variation in DRD2
allele prevalence (74,80,81). Some evidence
suggests that the Taqi A polymorphism is
in linkage disequilibrium with a functional
allelic determinant, including reported cor-
relations with DRD2 receptor number or
density (78,82) and with brain regional glu-
cose metabolism (83). Also, a better
response to treatment with a dopamine
receptor agonist has been reported among
alcoholics who carry the Al allele than
among those who do not (24,84).
A few studies have assessed DRD2poly-
morphisms and smoking behavior. The
TaqIAl allele was initially noted to be
more prevalent in smokers or ex-smokers
relative to nonsmokers (OR = 2.15 and
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1.71, respectively) (85). In a subsequent
study, the Al allele was most common
among those smokers who reported the
least success in quitting smoking, i.e.,
among those whose maximum quit attempt
was 1 week or less, 57.4% had at least one
copy of the Al allele, while among those
who had quit for 6 months or more, 33.3%
had the Al allele. The prevalence ofthe Al
allele also declined as the age at which sub-
jects first started smoking increased, and
was higher among those who smoked
greater amounts per day (86). In a third
study (60), among a subgroup ofindividu-
als with the DATI 9-repeat allele, there was
a significant association ofsmoking status
with the DRD2 Al allele, which was not
evident in the studypopulation as awhole.
DRD3. Expression of DRD3 appears
restricted to areas ofthe brain, induding the
NA, that are thought to playasignificant role
in addictive behavior (87). Lannfelt etal. (88)
reported a common point mutation (A to G)
in the first exon of DRD3, resulting in an
amino-acidsubstitution from serine to glycine
at codon 9 (Ser-9 to Gly), located at the N-
terminal extracellular domain ofthe receptor.
This amino acid substitution may modify
incorporation ofthe receptor protein into the
membrane (89). A number ofstudies have
assessed the relation ofthe DRD3 Ser-9 to
Gly polymorphism with schizophrenia [sum-
marized in Ebstein et al. (90]. Several have
reported excess homozygosity (ofeither allele)
of the Ser-9 to Gly polymorphism among
schizophrenic patients; others (90,91) have
observed an increased prevalence ofallele 2
(coding for glycine) in schizophrenics or no
association. Multiple studies have also been
conducted to assess the role ofthe Ser-9 to
Gly polymorphism in alcoholism (69,92-94)
and cocaine dependence (95). Although one
study (69) reported an increased frequency of
DRD3 allele 1 among alcohol-addicted
patients with delirium (p = 0.04), most stud-
ieshavefoundno association.
DRD4. The third exon of DRD4 con-
tains an unusually polymorphic 16-amino
acid repeat, and physiologic differences in
ligand binding have been observed between
the short (2-5 repeats; most commonly 4)
and long (6-10 repeats; most commonly 7)
forms of this repeat. In 1996, two studies
conducted in different populations (one in
Israel and one in the United States) report-
ed an association between the long allele of
the DRD4VNTR and the normal person-
ality trait of "novelty seeking" (27,28). A
subsequent study conducted in Finland
(96) failed to confirm this association.
Disease-related research involving this
polymorphism has included studies of
Parkinson's disease, bipolar disorder, schiz-
ophrenia, and alcoholism, most ofwhich
have not reported associations of the exon
3 DRD4 polymorphism and disease (97).
Other expressed polymorphisms in DRD4
are also known to occur, some of which
have been examined in association studies,
including a 12 bp duplication polymor-
phism and a 13 bp deletion, both located
in exon 1 (97-100).
DRD5. To date, the DRD5 gene has
been examined in only a few linkage stud-
ies of bipolar disorder, schizophrenia, or
Tourette's syndrome, with no evidence for
a major effect ofthis gene reported. Acom-
mon, silent polymorphism (Pro-326) has
been reported (101). Five polymorphisms
coding for amino acid changes have recent-
ly been identified for the D5 receptor; one
of these, a rare nonsense change predicted
to result in a 50% diminution offunctional
protein, has been examined in a case-con-
trol study of schizophrenia (102). A poly-
morphic dinucleotide repeat in the DRD5
promoter has also been identified, but is
not believed to be of functional signifi-
cance (103).
Metabolism
The majorendproduct ofdopamine metab-
olism in primates is HVA. Enzymes respon-
sible for metabolism ofdopamine to HVA
are COMT, MAO A and B, and aldehyde
dehydrogenase (38). An alternative metabol-
ic pathway for dopamine leads to the forma-
tion of norepinephrine; the DBH enzyme
catalyzes this conversion (104).
COMT. COMT is considered akey reg-
ulator of dopaminergic neurotransmission
(38,105). A common biallelic functional
polymorphism occurs within the COMT
gene resulting in high- and low-activity gene
products and a three- to fourfold variation
ofenzyme activity. This is due to a G to A
transition in the fourth exon of the gene,
resulting in a valine to methionine substitu-
tion at codon 158 ofthe membrane-bound
forms of COMT (corresponding to codon
108 of the soluble or cytoplasmic form)
(106). Homozygosity for the allele encoding
methionine is associated with low enzyme
activity and thermolability; homozygosity
for the allele encoding valine is associated
with high activity and thermostabiity; and
heterozygous individuals have an intermedi-
ate level ofCOMT activity and heat stabili-
ty (106). To date, this COMTgene poly-
morphism has been examined in relation to
Parkinson's disease, schizophrenia, obsessive
compulsive disorder, and bipolar disorder
(105,107-115), with most studies showing
no association. An intriguing possible associ-
ation with substance abuse has been noted,
with a higher proportion of substance
abusers than drug-free controls having high
activity COMTgenotypes (25).
MAO A andB. Genes encoding MAO
A and B are closely linked and are located
on the X chromosome. Abnormal MAO
enzyme activity levels have been associated
with a variety of conditions, including
smoking, alcoholism, schizophrenia, and
Parkinson's disease (36,37,116,117). In
1996, Fowler et al. reported that the brains
ofindividuals who currently smoke show a
40% reduction in MAO B enzyme relative
to never or former smokers (36), and that
MAO A enzyme levels are lower in smokers
than nonsmokers (37). In a cessation trial,
heavy smokers treated for 3 months with
moclobemide, a reversible inhibitor of
MAO A enzyme, had superior abstinence
rates for up to 6 months after quitting
compared with heavy smokers treated with
placebo (118).
Available data suggest that MAO
enzyme activity (measured in platelets and
fibroblasts) is under genetic control ofa sin-
gle major locus, possibly the MAO locus
itself, through noncoding, regulatory ele-
ments (117,119t). Several polymorphisms of
the MAO-A and MAO-B genes have been
identified; three polymorphisms of the
MAO-Agene have been shown to be associ-
ated with enzyme activity level, although
they do not affect the amino acid sequence
(119). One ofthese, located in exon 14 of
the MAO-A gene, has been assessed in a
case-control study ofParkinson's disease, in
which no assocation with disease risk was
evident (117).
Recently, the coding region of the
MAO-Bgene was screened for mutations by
dideoxy fingerprinting in 100 schizophrenic
patients; none were identified among the 80
white patients induded in that study (116).
A single base difference (A or G) in intron
13 ofthe AO-Bgene has been assessed in
case-control association studies of
Parkinson's disease and ofschizophrenia. In
some studies, the A allele was associated
with an approximately twofold increased
risk ofParkinson's disease (120,121), while
in another study (122), elevated risk ofthis
diseasewas observed amongindividuals with
the G allele. The effect of this polymor-
phism on brain activity, ifany, is unknown;
however, Costa et al. (122) note that it is
located in dose proximity to the 3' splicing
acceptor siteofintron 13 andcould conceiv-
ably be involved in mRNA processing. No
association of this polymorphism with risk
ofschizophrenia has been observed (117).
DBH. DBH catalyzes the conversion of
dopamine to norepinephrine. The DBH
gene has been examined in linkage and
association studies of schizophrenia
(123,124) and bipolar disorder (125). High
serum DBH enzyme activity has been asso-
ciated with alcohol consumption (126);
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also, an association ofserum DBH activity
with an intron 9 (two-allele) polymorphism
ofthis gene has been reported (127). A six-
allele polymorphic (GT)n repeat has also
been identified, with two alleles accounting
for more than 90% of alleles present in
individuals. It appears that DBH activity is
associated with this polymorphism
(124,127), with individuals homozygous
for theA3 and A4 alleles having lowest and
highest DBH activity, respectively, and
A3/A4 heterozygotes in an intermediate
range.
Other Interacting Neurotransmitters
Dopaminergic neurotransmission is influ-
enced by other neurotransmitters, such as
serotonin and norepinephrine (39,128).
Interactions between dopamine and other
neurotransmitter systems have been hypoth-
esized to potentially influence risk ofsome
neurologic conditions (e.g., schizophrenia,
depression), as well as response to therapy.
Polymorphisms of a variety of genes
involved in serotonergic neurotransmission
have been identified and, in a few cases,
examined in association studies (15). A
recent study (129) reported an association
between the personality trait of reward
dependence and a cysteine-to-serine substi-
tution in a serotonin receptor (HTR2C);
there was also a significant interaction
between polymorphisms of the dopamine
receptors DRD3 and DRD4 and the sero-
toninpolymorphism on rewarddependence.
Other Candidate Genes for Smoking
Behavior: Activityand Metabolism
ofNicotine
Nicotine is considered the most addictive
component in tobacco products (130).
Nicotine, via binding to neuronal nicotinic
receptors, enhances dopamine release and
neurotransmission in the mesolimbic
dopamine system. Chronic nicotine use
results in an increased density of nicotinic
receptors in various brain areas, and it is
thought that this increase may somehow
influence dependence on nicotine. One
model that has been proposed is that
chronic exposure to nicotine induces inac-
tivation ofsome receptors, which then turn
over more slowly, resulting in an increased
number of nicotinic receptors present. It
has been suggested that nicotine-induced
release of dopamine drives tobacco usage,
while receptor inactivation due to chronic
nicotine use may play a role in the process-
es oftolerance andwithdrawal (29).
Genetic differences in nicotinic receptor
activity or nicotine metabolism might rea-
sonably be hypothesized to play a role in
smoking addiction. Nicotinic cholinergic
receptors are diverse in subunit structure,
function, and distribution within the ner-
vous system; this diversity is likely to medi-
ate the complex actions ofnicotine in tobac-
co users (131). Nicotinic receptors are pre-
sent in the brain, autonomic ganglia, and
the neuromuscularjunction. Neuronal nico-
tinic acetylcholine receptors are believed to
be most relevant to nicotine addiction; these
are located throughout the brain and are
composed ofa and P subunits, most com-
monly (90%) as the a4, ,B2 receptor (131).
The identification and characterization of
polymorphisms in the a4 subunit of the
neuronal nicotinic acetylcholine receptor
(CHRNA4) is an area of active research
(132-135). This gene has been hypothesized
to play a role in various neurologic condi-
tions induding epilepsy and panic disorder.
To date, onlyone association studyhas been
conducted; in that study, no differences in
the allele frequency of any of three silent
polymorphisms ofthe CHRNA4 gene were
noted in a comparison of 88 patients with
panicdisorder andhealthycontrols (133).
Considerable interindividual variability
exists in the metabolism ofnicotine (131).
Approximately 70-80% of nicotine is
metabolized to cotinine in a two-step
process. The first step, in which nicotine is
converted to nicotine iminium, is metabo-
lized by a CYP450 enzyme, most likely
CYP2A6 (131,136). Interindividual differ-
ences in the activity of CYP2A6 exist, and
two variant CYP2A6alleles (CYP2A6vJ
and CYP2A6v2) have been identified
(137,138). CYP2A6vJ has a T to A muta-
tion, creating an amino acid change (Leu-
160 to His), and CYP2A6v2 has a C to A
mutation; both mutations occur in exon 3.
Subjects homozygous for CYP2A6vJ have
undetectable coumarin metabolism (a
process dependent on CYP2A6), whereas
heterozygotes for CYP2A6vJ have levels of
coumarin metabolism that are 50-60%
that of the general population. The func-
tionalityofCYP2A6v2 is notyet known.
Another P450 enzyme, CYP2D6, is
known to be polymorphic, and in white
populations is inactive in 5-10% ofindivid-
uals (139). Individuals are often referred to
as poor metabolizers (PMs) or extensive
metabolizers (EMs), based on a correlation
of CYP2D6genotype with the phenotypic
ability to metabolize debrisoquine; PMs lack
CYP2D6 activity because of inactivating
mutations in both alleles ofthe gene (located
at 22ql3.1). CYP2D6 has been suggested to
be involved in the metabolism of nicotine
(140), although this has recently been ques-
tioned (141). CYP2D6 is active in both the
liver and the brain, and the distribution of
CYP2D6 is similar to that of the dopamine
transporter (142). Some research suggests
that personality characteristics may differ by
CYP2D6genotype and/or the associated
debrisoquine metabolizer phenotype, and it
has been hypothesized that an endogenous
neuroactive substance involved in dopamine
neurotransmission may be a substrate of
CYP2D6 in brain (142-144). In some stud-
ies, CYP2D6 PMs have been observed to be
at increased risk of Parkinson's disease, and
studies are currently in progress to evaluate
the role of CYP2D6 in opiate addiction
(145). Turgeon (146) reported that none of
58 healthy smokers <35 years ofage had the
PM phenotype, compared to 10% of 200
nonsmoking white controls from the same
population. In contrast, Cholerton et al.
(147) found no difference in CYP2D6geno-
type in a comparison of 100 cigarette smok-
erswith 104 nontobacco users aged 18-61.
Data regarding correlations between
smoking prevalence and polymorphisms in
other P450 enzymes are extremely limited.
Recently, an association of the CYPlAI
MspIgenotype with pack-years of smoking
was reported in two independent samples of
healthy, white control populations (148).
Summary
Twin and family studies have contributed
evidence ofa genetic component in smok-
ing addiction and in specific aspects of
smoking behavior such as initiation and
quitting. These studies provide an impetus
for the identification ofspecific genes that
may be involved. A rather large number of
candidate genes for smoking behavior-
that is, genes involved in dopaminergic
neurotransmission or in the activity and
metabolism ofnicotine-have been identi-
fied; however, few studies have examined
the relation ofthese genes to smoking. For
many of the genes of interest, polymor-
phisms have been identified only recently.
Among identified polymorphisms, there is
a range of likely functional significance,
including those of known, possible, and
unknown functionality. Given the rapidity
with which knowledge regarding dopamin-
ergic genes is accumulating, as well as the
possibility that other neurologic gene prod-
ucts (e.g., those involved in serotonergic
gene transmission) may also influence
addictive behavior, it is likely that addi-
tional gene polymorphisms of relevance to
smoking behavior will be identified during
the next several years.
As population rates of smoking decline
in response to social pressures, genetic influ-
ences may be particularly strong among the
remaining smokers. Understanding the
genetic influences on smoking initiation
may allow targeting ofprevention strategies
to individuals at highest risk. Increased
understanding of genetic influences on the
ability to quit smoking may lead to the
Environmental Health Perspectives * Volume 106, Number 5, May 1998 235Reviews * Rossing
identification ofgenetic subgroups of indi-
viduals who are most likely to benefit from
particular pharmacologic interventions for
smokingcessation.
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